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Abstract
Background: Myocardial scarring at the LV pacing site leads to incomplete resynchronization and a suboptimal
symptomatic response to CRT. We sought to determine whether the use of late gadolinium cardiovascular
magnetic resonance (LGE-CMR) to guide left ventricular (LV) lead deployment influences the long-term outcome of
cardiac resynchronization therapy (CRT).
Methods: 559 patients with heart failure (age 70.4 ± 10.7 yrs [mean ± SD]) due to ischemic or non-ischemic
cardiomyopathy underwent CRT. Implantations were either guided (+CMR) or not guided (-CMR) by LGE-CMR prior
to implantation. Fluoroscopy and LGE-CMR were used to localize the LV lead tip and and myocardial scarring
retrospectively. Clinical events were assessed in three groups: +CMR and pacing scar (+CMR+S); CMR and not
pacing scar (+CMR-S), and; LV pacing not guided by CMR (-CMR).
Results: Over a maximum follow-up of 9.1 yrs, +CMR+S had the highest risk of cardiovascular death (HR: 6.34),
cardiovascular death or hospitalizations for heart failure (HR: 5.57) and death from any cause or hospitalizations for
major adverse cardiovascular events (HR: 4.74) (all P < 0.0001), compared with +CMR-S. An intermediate risk of
meeting these endpoints was observed for -CMR, with HRs of 1.51 (P = 0.0726), 1.61 (P = 0.0169) and 1.87 (p =
0.0005), respectively. The +CMR+S group had the highest risk of death from pump failure (HR: 5.40, p < 0.0001)
and sudden cardiac death (HR: 4.40, p = 0.0218), in relation to the +CMR-S group.
Conclusions: Compared with a conventional implantation approach, the use of LGE-CMR to guide LV lead
deployment away from scarred myocardium results in a better clinical outcome after CRT. Pacing scarred
myocardium was associated with the worst outcome, in terms of both pump failure and sudden cardiac death.
Background
Cardiac resynchronization therapy (CRT) is an estab-
lished treatment for symptomatic patients with heart
failure, severe left ventricular (LV) systolic dysfunction
and a prolonged QRS duration. The Cardiac Resynchro-
nization Heart Failure (CARE-HF) study showed that
CRT-pacing (CRT-P) was associated with 36% reduction
in all-cause mortality. [1] The Comparison of Medical
Therapy, Pacing and Defibrillation in Heart Failure
(COMPANION) study showed that addition of a
cardioverter defibrillator (CRT-D) leads to a greater sur-
vival benefit. [2] Additional benefits include reductions
in heart failure hospitalizations as well as improvements
in symptoms, exercise capacity and quality of life. [1-4]
T h ev a r i a b i l i t yo ft h er e s p o n s et oa n do u t c o m eo f
CRT has been a subject of increasing attention [4,5].
Left ventricular (LV) lead position may be relevant in
this respect. From the mechanical and electrophysiologi-
cal perspectives, pacing scar is bound to be less effective
than pacing viable myocardium. This notion is sup-
ported by cardiovascular magnetic resonance (CMR)
[6,7] and nuclear scintigraphy [8] studies showing that
myocardial scarring in the vicinity of the LV lead tip
leads to a suboptimal response to CRT. These studies,
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not included patients with non-ischemic cardiomyopa-
thy and have not addressed long-term clinical outcomes.
In this large study of consecutive patients undergoing
CRT, we have assessed whether the use of late gadoli-
nium enhancement (LGE)-CMR scan to guide deploy-
ment of the LV lead in a non-scarred segment of the
LV free wall leads to a better long-term outcome from
CRT than using a conventional implantation approach.
Methods
Patients
Inclusion criteria were as follows: heart failure in NYHA
class III or IV; attendance to a dedicated heart failure
clinic with the aim of achieving maximum tolerated
treatment with angiotensin-converting enzyme inhibitors
(ACE-I) or angiotensin II receptor blockers (ARBs),
beta-blockers and spironolactone, and; a QRS duration
≥120 ms; LVEF ≤ 35%. Exclusion criteria were: contrain-
dications to cardiac pacing; myocardial infarction or
acute coronary syndrome within the previous month;
severe structural valvular heart disease; presence of
comorbidities likely to threaten survival for 12 months.
All participants had undergone coronary angiography.
The diagnosis of heart failure was made on the basis of
echocardiographic evidence of LV systolic dysfunction.
The diagnosis of ischemic cardiomyopathy was made if
LV systolic dysfunction was associated with a history of
myocardial infarction [9] and if there was angiographi-
cally documented coronary heart disease (> 50% stenosis
in ≥ 1 coronary arteries). The findings of LGE-CMR
were also used to ascertain the etiology of heart failure:
[10] LV dysfunction in combination with transmural or
subendocardial LGE was regarded as ischemic cardio-
myopathy whereas LV dysfunction and no LGE, patchy
uptake or mid-wall LGE was regarded as non-ischemic
cardiomyopathy. The study conforms with the Declara-
tion of Helsinki. This study was approved by the local
Ethics Committee.
Study design
This study consisted of patients who underwent CRT on
the basis of accepted indications in the period from Sep-
tember 2000 to June 2009. As national guidance and
funding for CRT-D in the United Kingdom was not
issued until 2007, [11] CRT-P was only CRT modality
available for most patients.
Patients underwent a clinical assessment on the day
prior to implantation and at 1, 3, and every 6 months
following device implantation. The LGE-CMR scan
was undertaken within a month prior to implantation.
In patients who died, the clinical and echocardio-
g r a p h i cd a t aa tf o l l o w - u pp e r t a i n st ot h el a t e s ta v a i l -
able follow-up.
Prior to the demonstration that myocardial scarring at
the site of LV lead deployment is associated with a sub-
optimal response to CRT, [7] the implanters were
blinded to the results of the LGE-CMR. Following this
demonstration, the LGE-CMR was used to guide LV
lead deployment. For analysis, patients were grouped
into the following categories: +CMR and pacing scar
(CMR+S, n = 43); CMR and not pacing scar (+CMR-S,
n = 166), and; LV pacing not guided by CMR (-CMR, n
= 350).
Clinical assessment and echocardiography
This included evaluation of NYHA functional class and
a 6-min hall walk test [12]. Response in terms of the
composite clinical score (CCS) was defined as: survival
for one year following implantation; no hospitalizations
for heart failure for one year following implantation,
and; improvement by ≥1 NYHA classes or by ≥25% in
6-min walking distance. Two-dimensional echocardio-
graphy was performed using a Vivid Systems 5 and 7
scanners (General Electric Healthcare Worldwide,
Slough, United Kingdom). An echocardiographic
response, denoting LV reverse remodeling, was defined
as a ≥15% reduction in LV end-systolic volume (LVESV)
at follow-up.
CMR
Images were acquired on a 1.5 Tesla scanner (Signa,
General Electric Healthcare Worldwide, Slough, United
Kingdom) using a phased array cardiac coil during
repeated 8-second breathholds. A short axis stack of left
ventricular images was acquired using a steady state in
free precession (SSFP) sequence (repetition time 3.0 to
3.8 ms; excitation time 1.0 ms; image matrix 224 × 224;
field of view 36-42 cm; flip angle 45°) in sequential 8
mm slices (2 mm interslice gap) from the atrioventricu-
lar ring to apex. For the LGE-CMR study, gadolinium-
diethylenetriamine pentaacetic acid (0.1 mmol/kg) was
administered intravenously and images were acquired
after 10 minutes using a segmented inversion-recovery
technique in identical short-axis slices, as previously
described [7]. Inversion times were adjusted to null nor-
mal myocardium (260 to 400 ms). Infarct volume was
calculated in cm
3 by multiplying the planimetered area
in each segment by the slice thickness. Scar volume was
expressed as a % of LV myocardial volume in the diasto-
lic phase.
Device therapy
Patients underwent transvenous CRT device implanta-
tions using cephalic, subclavian or femoral vein
approaches. If a LGE-CMR was available, implanters
were asked to deploy the LV lead away from scarred
myocardium, if at all possible. The operator, however,
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other lead parameters or pacing characteristics were
unsatisfactory.
Lead position
The segmental position of the LV lead tip was deter-
mined with reference to its longitudinal (base-to-apex)
and its circumferential position, using a dedicated ima-
ging programme (available free at http://www.osirix.
com) (Figure 1). The LV lead tip was considered to be
in a scarred segment if this contained scar in any distri-
bution (transmural or non-transmural). Lead positions
were assessed retrospectively by a senior radiographer
and by a cardiologist who were blinded to the clinical
outcome data.
Follow-up
Patients were entered into the study after optimization
of medical therapy and a successful implantation.
Thereon, they were followed-up in a dedicated CRT
clinic. Patients in sinus rhythm underwent transmitral
Doppler-directed optimization of atrioventricular delay
[13] prior to discharge and at every scheduled visit
thereafter. Backup atrial pacing was set at 60 beats/min,
and the pacing mode was set to DDD with an interven-
tricular delay of 0-4 ms, depending on the manufacturer.
For patients in chronic atrial fibrillation, right ventricu-
lar and LV leads were implanted and a CRT generator
was used, plugging the atrial port and programming the
generator to a ventricular-triggered mode.
Endpoints
The clinical endpoints considered were cardiovascular
mortality; the composite of death from any cause or an
unplanned hospitalization for major adverse cardiovas-
cular events (MACE), which included cardiac transplan-
tation, hospitalizations for worsening heart failure,
myocardial infarction, acute coronary syndromes,
arrhythmia, stroke or pulmonary embolism; the compo-
site end point of death from any cause and unplanned
hospitalization with worsening heart failure. For all end-
points, the first event was included in analyses. Sudden
Figure 1 Mapping LV lead positions. Example of the main screen of the software programme used for mapping LV lead positions. The
longitudinal distance from the atrioventricular plane to the lead tip, in a base-to-apex direction, is quantified in mm using the 30° right anterior
oblique fluoroscopic view (upper left hand panel). This longitudinal distance is transposed to the four-chamber CMR view (upper right hand
panel), so as to determine the LGE-CMR short axis slice (yellow line, left lower panel) that corresponds to the LV lead tip position. The 30° left
anterior oblique fluoroscopic view (right lower panel) is then used to determine the circumferential position (yellow arrow). The longitudinal and
circumferential coordinates permit localization of the LV lead tip in relation to myocardial segments [35] and myocardial scars, which appear as
white enhancement on LGE-CMR (white arrow).
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death due to cardiac causes, heralded by an abrupt loss
of consciousness within one hour of the onset of acute
symptoms.”[14]Death from pump failure was defined as
‘death after a period of clinical deterioration in signs
and symptoms of heart failure despite medical treat-
ment’.[15] Clinical outcome data was collected prospec-
tively through medical records, and where appropriate,
from interviews with patient’s caregivers. Information
regarding clinical outcome was collected by an investiga-
tor who was blinded to the results of the CMR study
and LV lead position data.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation (SD). Normality was tested using the Shapiro-
Wilk test (the W-statistic). Comparisons between normally
distributed continuous variables were made using
ANOVA with Fisher’s Protected Least Significance Differ-
ence test for multiple comparisons. Categorical variables
were analyzed using chi-squared tests. Group differences
with respect to the various endpoints was explored using
Kaplan-Meier survival curves and the log-rank test (Man-
tel-Cox). Univariate and multivariable Cox proportional
hazards analyses were also used to explore the
relationships between the groups and the various end-
points. Statistical analyses were performed using Statview
(Cary, NC) and SPSS 13.0 (Chicago, Illinois). A two-tailed
p value of < 0.05 was considered statistically significant.
Results
In the period September 2000 to June 2009, 559 consecu-
tive, successful CRT implantations were undertaken for
standard indications at a single centre (Good Hope Hos-
pital). A total of 87/559 (16%) underwent CRT-D whilst
the remainder underwent CRT-P. In the whole cohort,
367/559 (66.7%) patients had ischemic cardiomyopathy
and 192/559 (34.3%) had non-ischemic cardiomyopathy.
As shown in Table 1, there were significant group dif-
ferences with respect to pre-implant age, NYHA class,
QRS duration, history of coronary artery bypass opera-
tion and presence of chronic atrial fibrillation. Over a
maximum follow-up period of 3323 days (median: 666
days), there were 181 deaths from all causes. Of these,
149 were due to cardiovascular causes, including 2
patients who underwent cardiac transplantation.
Clinical endpoints
As shown in Figure 2, the +CMR+ S group had the highest
risk of cardiovascular death, the composite endpoint of
Table 1 Clinical Characteristics of the Study Group
P
All A
-CMR
B
+CMR-S
C
+CMR+S
Bv sA Cv sA Cv sB
N 559 350 166 43
Age, yrs 70.4 ± 10.7 71.6 ± 10.7 68.3 ± 10.6 68.5 ± 10.6 0.0007 0.0704 0.8714
Men, n (%) 436 (78) 275 (79) 123 (74) 38 (88) 0.1203
NYHA class 3.31 ± 0.5 3.35 ± 0.5 3.20 ± 0.40 3.37 ± 0.49 0.0004 0.8115 0.0287
III 385 (69) 225 (64) 133 (80) 27 (63)
CRT-D, n (%) 87 (16) 52 (15) 27 (16) 8 (19) 0.7799
Co-morbidity, No. (%)
Diabetes mellitus 90 (16) 55 (16) 25 (15) 10 (24) 0.4248
Hypertension 149 (27) 93 (17) 44 (27) 12 (28) 0.9575
Coronary artery bypass 112 (20) 65 (19) 30 (18) 17 (40) 0.0048
Medication, No. (%)
Loop diuretics 495 (89) 314 (90) 144 (87) 37 (86) 0.2619
ACE-I or ARB 498 (89) 306 (87) 151 (91) 41 (95) 0.3392
Beta-blockers 300 (54) 177 (51) 97 (58) 26 (60) 0.2641
Spironolactone 224 (40) 138 (39) 65 (39) 17 (40) 0.9142
ECG variables
Chronic atrial fibrillation,
No. (%)
119 (21) 86 (25) 29 (17) 4 (9) 0.0249
QRS duration, ms 154.3 ± 28.5 158.5 ± 29.5 148.6 ± 25.4 144.5 ± 26.0 0.0003 0.0022 0.3860
Echocardiography
LVEDV, mL 259.0 ± 109.0 252.5 ± 107.2 268.3 ± 115.1 267.5 ± 97.2 0.1938 0.4489 0.9703
LVESV, mL 200.9 ± 94.5 196.5 ± 92.2 207.2 ± 101.2 206.0 ± 83.8 0.3109 0.5820 0.9466
LVEF, % 23.5 ± 10.1 23.2 ± 10.4 24.1 ± 9.9 23.7 ± 8.6 0.4346 0.7832 0.8465
+CMR-S = CMR showing no scar at the LV pacing position; +CMR+S = CMR showing scar at the LV pacing position; -CMR = non-CMR guided group.
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and the composite endpoint of death from any cause or
hospitalizations for MACE (all P < 0.00001). In Cox pro-
portional hazards models, age, NYHA class, QRS duration,
history of CABG and of chronic AF were entered as
covariables. With reference to the adjusted HRs (Table 2),
the +CMR+S group had the highest risk of cardiovascular
death (HR: 6.34), the composite endpoint of cardiovascular
death or hospitalizations for heart failure (HR: 5.57) and
the composite endpoint of death from any cause or hospi-
talizations for MACE (HR: 4.74) (all P < 0.0001), com-
pared with the +CMR-S group. The -CMR group had a
intermediate risk of meeting these endpoints, with HRs of
1.51 (P = 0.0726), 1.61 (P = 0.0169) and 1.87 (p = 0.0005),
respectively.
In further analyses, the +CMR-S group was split into
patients with non-ischemic cardiomyopathy (n = 74)
and patients with ischemic cardiomyopathy (n = 92). In
Cox proportional hazards analyses, there were no differ-
ences with respect to cardiovascular death (HR: 0.59
[95% CI: 0.26 to 1.31], p = 0.1906) or any other end-
point (data not shown). The +CMR-S group was also
subdivided according to scar burden. In receiver opera-
tor characteristic curves (ROC), a scar burden cut-off of
≥10% was associated with a sensitivity of 81.1% and a
specificity of 40.0% for the detection of cardiovascular
death (p < 0.0001). A scar burden of < 10% predicted
survival from cardiovascular death (HR: 0.37, 95% confi-
dence interval [CI]: 0.17 to 0.81, c
2 = 6.12, p = 0.0134),
the composite endpoint of cardiovascular death or hos-
pitalizations for heart failure (HR: 0.36, 95% CI: 0.17 to
0.75, c
2 = 7.60, p = 0.0058) and the composite endpoint
of death from any cause or hospitalizations for MACE
(HR: 0.50, 95% CI: 0.26 to 0.98, c
2 = 4.09, p = 0.0432).
Mode of death
Out of 149 cardiovascular deaths, 107 were due to pump
failure (including 2 patients who underwent cardiac trans-
plantation), 39 were sudden and 3 were due to myocardial
infarction. As shown in Table3, +CMR+S group had the
highest risk of death from pump failure (HR: 5.40, p <
0.0001) and sudden cardiac death (HR: 4.40, p = 0.0218). As
evidenced by the much higher c
2, the association between
+CMR+S and pump failure ( c
2 = 29.1) was stronger than
with sudden cardiac death (c
2 = 5.26).In the +CMR-S
group, patients with a scar burden of < 10% had a lower
risk of death from pump failure (HR: 0.28, 95% CI: 0.11 to
0.71, c
2 = 7.34, p = 0.0067), but not of sudden cardiac death
(HR: 0.43, 95% CI: 0.07 to 2.59, c
2 = 0.85, p = 0.3581), com-
pared with patients with a scar burden of ≥10%.
Clinical response
NYHA class was available in 532 patients at a median
follow-up period of 287 days (interquartile range: 463.7
days). Of these, 428 (80%) had improved by ≥1c l a s sa t
follow-up. Baseline 6-min walking distance was available
in 333 patients (217.8 ± 113.8 m). Follow-up 6-min walk
tests were available in 226 patients. In the whole cohort,
6-min walking distance increased by ≥25% in 106
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Figure 2 Clinical outcome of CRT according to implantation
strategy. +CMR-S = group with CMR showing no scar at the LV
pacing position; +CMR+S = group with CMR showing scar at the LV
pacing position; -CMR = non-CMR guided group.
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Page 5 of 9(51.2%) patients. Of the 553 patients in whom there was
sufficient data to classify in terms of the composite clini-
cal score, 385 (70%) were classified as responders. As
shown in Figure 3a, the CMR-S group had the best clin-
ical response, compared with the CMR+S group (P <
0.00001) and the -CMR group (P = 0.0382)
In the +CMR-S group, a scar burden of < 10% was
not associated with a better composite clinical score
compared with a scar burden of ≥10% (p = 0.7281).
LV reverse remodeling
Amongst patients with complete follow-up echocardio-
graphy at the last available clinical visit (n = 320), LV
reverse remodeling was less pronounced in the +CMR
+S group (31%) than in the -CMR group (p = 0.0382).
There was a trend towards a better response in the
CMR-S group than in the +CMR+S group, but this was
not statistically significant (P = 0.0799) (Figure 3b).
In the +CMR-S group a scar burden of < 10% was not
associated with a better LV reverse remodeling response
compared with a scar burden of ≥10% (p = 0.3500).
Discussion
The hypothesis addressed in this study is that, compared
with a conventional approach, the use of LGE-CMR for
guiding LV lead deployment away from scarred myocar-
dium leads to a better outcome from CRT. We have
shown that scarring in the myocardial segment sub-
tended by the LV lead tip has a dramatic negative effect
outcome of and response to CRT. Compared with
pacing non-scar, pacing scar was associated with an
over 6-fold increase in the risk of cardiovascular death.
An implantation strategy which did not include LGE-
CMR was associated with a worse outcome than a strat-
egy of pacing non-scar, in terms of the composite end
points and the composite clinical score. Although pacing
scar had a particularly strong relationship with death
from pump failure, it was also associated with a higher
risk of sudden, presumed arrhythmic, death.
The importance of myocardial viability in determining
the response to treatments, such as revascularization
[16-18] and beta-blockade for heart failure, [19] is well
recognized. The concept that myocardial viability of the
myocardium subtended by the LV lead is important in
determining the response to CRT has been supported
by several small studies [6-8]. In the present study of a
large cohort of patients with ischemic or non-ischemic
cardiomyopathy, we have found that, compared to LV
deployment over non-scarred myocardium, deployment
over scarred myocardium is associated with a higher
risk of cardiovascular death, hospitalizations for heart
failure and for MACE. In addition, pacing scarred myo-
cardium was also associated with a markedly reduced
clinical response in terms of the composite clinical
score. These findings are consistent with the fact that
pacing a scar is associated increased duration [20,21]
and fragmentation of the QRS complex, as well as sub-
optimal mechanical resynchronization [22]. Moreover, it
has been shown that myocardial scars are not readily
excitable [23] and that they reduce the volume of excita-
ble myocardium available to a LV pacing stimulus [24].
We have observed a trend towards a less pronounced
LV reverse remodeling in the group of patients with LV
leads deployed over scarred myocadium. Although the
difference between the +CMR+S and the -CMR groups
were statististically significant, with a lower response in
the +CMR+S group, the difference between the +CMR
+S and the +CMR-S groups was not significant. This,
h o w e v e r ,i sl i k e l yt ob ed u et ot h er e l a t i v e l yl o wn u m -
bers of patients included in these subgroups. Notwith-
standing, the trend towards less LV reverse remodeling
in the +CMR+S group is consistent with other studies
[22] and could partly explain the associated effects on
outcome and response. Importantly, however, LV remo-
deling is not the only mechanism involved in CRT.
Relief of the diastolic ventricular interaction, [25] and a
Table 2 Effects of implantation strategy on clinical outcomes
Cardiovascular death Cardiovascular death / hospitalizations for HF Death from any cause / hospitalizations for MACE
HR (95% CI) * p HR (95% CI) * p HR (95% CI) * p
+CMR+S 6.34 (3.64 to 11.0) < 0.0001 5.57 (3.40 to 9.14) < 0.0001 4.74 (2.95 to 7.62) < 0.0001
-CMR 1.51 (0.96 to 2.36) 0.0726 1.61 (1.09 to 2.38) 0.0169 1.87 (1.31 to 2.66) 0.0005
*, Hazard ratios (HR) and 95% confidence intervals (CI) refer to the risk of meeting the endpoints in comparison to the group in which CMR was performed and
the LV lead was deployed in non-scarred myocardium. Adjustment has been made for age, NYHA class, QRS duration, history of CABG and of chronic atrial
fibrillation in Cox proportional hazards analyses. +CMR+S = CMR showing scar at the LV pacing position; -CMR = non-CMR guided group.
Table 3 Effects of implantation strategy on mode of
death
Death from pump failure Sudden cardiac death
HR (95% CI) * c
2 p HR (95% CI) * c
2 p
+CMR
+S
5.40 (2.92 to
9.94)
29.1 <
0.0001
4.40 (1.24 to
15.62)
5.26 0.0218
-CMR 1.12 (0.67 to
1.85)
0.13 0.6847 2.93 (1.11 to
7.76)
4.71 0.0299
*, Hazard ratios (HR) and 95% confidence intervals (CI) refer to the risk of
meeting the endpoints in comparison to the group in which CMR was
performed and the LV lead was deployed in non-scarred myocardium.
Adjustment has been made for age, NYHA class, QRS duration, history of
CABG and of chronic atrial fibrillation in Cox proportional hazards analyses.
+CMR+S = CMR showing scar at the LV pacing position; -CMR = non-CMR
guided group.
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additional mechanisms that are at play in CRT. These
mechanisms are not necessarily dependent on reverse
LV remodeling [27,28].
Compared with the +CMR-S group, the +CMR+S
group also had a higher risk of sudden cardiac death.
These findings have emerged in the context that pacing
over scar or the border zone of scar can be arrhythmo-
genic.[29-32]In a study of 47 ICD candidates, Schmidt
et al a relationship between inducibility of arrhythmias
and heterogenetity in the border zone of scar.[33]In
addition, the extent of the border zone of scar is a
strong predictor of spontaneous ventricular arrhythmias
and subsequent ICD therapy in patients with ischemic
cardiomyopathy, with or without a history of ventricular
arrhythmias.[34]
In analyses of patients in whom the LV lead had been
deployed away from scarred myocardium, a low scar
burden (< 10%) was associated with a better clinical out-
come, in terms of all endpoints. In terms of mode of
death, a scar burden of > 10% was associated with a
higher risk of death from pump failure, but not sudden
cardiac death. These findings are perhaps not surprising,
as increasing scar burden equates with poor myocardial
function. Importantly, however, scar burden did not
appear to influence LV reverse remodelling, nor the
composite clinical score. On the basis of these findings,
ah i g hs c a rb u r d e n( ≥10% ) in +CMR-S patients does
not necessarily discount a symptomatic benefit from
CRT.
Several studies have shown that an ischemic etiology
has a negative effect on the outcome of CRT. In our
whole cohort, etiology of heart failure did indeed
emerge as a predictor of the various endpoints. How-
ever, this was no longer the case when patients in the
+CMR+S group were excluded. This indicates that the
observed differences in the response to and outcome of
CRT is due to deployment of the LV lead over scarred
myocardium. Admittedly, the numbers included in this
subanalysis are relatively small and one cannot exclude
the possibility that the outcome of CRT is better in
non-ischemic cardiomyopathy, regardless of LV lead
position. Notwithstanding, it appears that the outcome
of CRT in ischemic cardiomyopathy approximates to
that of non- ischemic cardiomyopathy, as long as the
LV lead is deployed over non-scarred myocardium.
Limitations
This is an observational study and therefore, our find-
ings should be interpreted with caution. The groups
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meeting the respective endpoints by the end of the study.
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Page 7 of 9analyzed were not matched for baseline variables and
although this was taken into account in statistical ana-
lyses, a biological effect of the covariables cannot be dis-
counted. These findings should ideally be explored in a
randomized, controlled study. Given the currently avail-
able evidence on the detrimental effects of myocardial
scarring at the LV pacing site, however, it is unlikely
that a randomized study would be undertaken. We have
not included a control group not treated with CRT and
therefore, we cannot determine whether patients in
highest risk category (+CMR+S) benefit to the same
degree as patients treated with drug treatment alone. A
randomized study of drug treatment versus CRT, how-
ever, is no longer ethically justifiable. This study did not
address the relationship of LV lead pacing site to regio-
nal mechanical dyssynchrony, which is thought to be
valuable in determining response.
Conclusions
We conclude that, compared with a conventional implan-
tation approach, the use of LGE-CMR to guide LV lead
deployment away from scarred myocardium results in a
better clinical outcome after CRT. On this basis, we
would recommend the use of LGE-CMR in the routine
pre-implant work-up of patients undergoing CRT.
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